

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: **Kasper Mathias Antoon ROUSCHOP *et al.***

Application No. **10/593,296**

Filing Date: **September 18, 2006**

Confirmation No. **7543**

Group Art Unit: **Not Assigned**

Examiner: **Not Assigned**

For: **CD44-targeting for reducing/preventing ischemia-reperfusion-injury**

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)**

Pursuant to 37 C.F.R. 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

Copies of the listed documents are attached. With the exception of reference 15, documents of the listed documents were cited in an International Search Report which issued in a corresponding PCT application, International Application PCT/NL2005/000200.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due

under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **Constructive Petition for Extension of Time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **July 12, 2007**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Ave., N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted  
**Morgan, Lewis & Bockius LLP**

  
\_\_\_\_\_  
Robert Smyth  
Registration No. 50,801

<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)  <b>PTO Form 1449</b>				Attorney Docket <b>067131-5001</b>		Application No: <b>10/593,296</b>			
				Applicants: <b>Kasper Mathias Antoon ROUSCHOP <i>et al.</i></b> Page 1 of 1					
				Filing Date: <b>September 18, 2006</b>		Group Art Unit: <b>Not Assigned</b>			
<b>U.S. PATENT DOCUMENTS</b>									
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
	1	2002/0160010	10/31/02	Herrlich <i>et al.</i>	424	184.1	11/02/99		
	2	5,674,857	10/07/97	Falk <i>et al.</i>	514	54	02/23/94		
	3	5,951,982	09/14/99	Zoller <i>et al.</i>	424	154.1	12/20/94		
<b>FOREIGN PATENT DOCUMENTS</b>									
		Document No.	Date	Country	Class	Sub-Class	Translation		
	4	EP 0538754	04/28/93	EP	A61K	39/395	No		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>									
	5	Brennan <i>et al.</i> , CD44 is involved in selective leucocytes extravasation during inflammatory central nervous system disease, Immunology, 98: 427-435 (1999).							
	6	Cabrera <i>et al.</i> , Modulacion de isoformas de la molecula de adhesion CD44 en un modelo murino de isquemia y reperfusion intestinal, Medicina (Buenos Aires), 60: 940-946 (2000).							
	7	DeGrendele <i>et al.</i> , Requirement for CD44 in activated T cell extravasation into an inflammatory site, Science, 278: 672-675 (1997).							
	8	Hutter <i>et al.</i> , CD44 and hyaluronate are involved in platelet-endothelial cell interaction after ischemia-reperfusion, European Surgical Research, 33: 51-52 (2001).							
	9	Katoh <i>et al.</i> , Characterization of soluble CD44 in the circulation of mice: Levels are affected by immune activity and tumor growth, Journal of Immunology, 153: 3440-3449 (1994).							
	10	Knoflach <i>et al.</i> , Immunomodulatory functions of low-weight hyaluronate in an acute rat renal allograft rejection model, Journal of the American Society of Nephrology, 10: 1059-1065 (1999).							
	11	Mueller <i>et al.</i> , L-arginine application improves graft morphology and mucosal barrier function after small bowel transplantation, Transplantation Proceedings Sep., 32: 1275-1277 (2000).							
	12	Seiter <i>et al.</i> , Down-modulation of host reactivity by anti-CD44 in skin transplantation, Transplantation (Baltimore), 66: 778-791 (1998).							
	13	Tanaka <i>et al.</i> , Anti-CD44 monoclonal antibody (IM7) induces systemic shock mediated by platelet activating factor, Journal of Autoimmunity, 18: 9-15 (2002).							
	14	Wang <i>et al.</i> , Discovery of induced CD44 gene expression after focal brain ischemia in both rats and mice, Society for Neuroscience Abstracts, 26: 670.9 (2000).							
	15	Wang <i>et al.</i> , CD 44 deficiency in mice protects brain from cerebral ischemia injury, Journal of Neurochemistry, 83: 1172-1179 (2002).							
Examiner			Date Considered						
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									